Cure My Disease

Don't miss your cure!

 Log in / Sign up

New painkiller may cut opioid use after abdominal surgery

NCT ID NCT06737341

Recruiting now Symptom relief Sponsor: Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study tests whether a long-acting form of the painkiller bupivacaine (called liposomal bupivacaine) can reduce the need for opioid pain medicine after laparoscopic liver, gallbladder, or pancreas surgery. Sixty adults aged 18–80 will receive either the long-acting painkiller mixed with regular bupivacaine or regular bupivacaine alone, both injected near the ribs under ultrasound guidance. The main goal is to see if the long-acting version lowers total opioid use in the first 72 hours after surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANALGESIA, POSTOPERATIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

agnosia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANALGESIA, POSTOPERATIVE BUPIVACAINE OPIOIDS ULTRASOUND GUIDED

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-••••

Locations

  • Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. 1095 Jiefang Avenue, Wuhan City, Hubei Province

    NOT_YET_RECRUITING

    Wuhan, Hubei, 430030, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Tongji Hospital

    RECRUITING

    Wuhan, Hubei, 430030, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.